ライフサイエンスコーパス: insulinoma

1 actor in insulin-secreting beta-cell tumors (insulinomas).

2 y severe hypoglycemic events or diagnoses of insulinoma.

3 patient, there was no radiologic evidence of insulinoma.

4 tumor stroma in a mouse model of pancreatic insulinoma.

5 a successful hand-assisted enucleation of an insulinoma.

6 n pancreatic neuroendocrine tumors including insulinoma.

7 glycaemia especially in suppression tests of insulinoma.

8 or MR imaging) was not able to localize the insulinoma.

9 rs (insulinomas), and also in human sporadic insulinomas.

10 endin-4 ((111)In-DTPA-exendin-4) to identify insulinomas.

11 a may overlap with those in patients without insulinomas.

12 rgical resection of histologically confirmed insulinomas.

13 consistent, abnormal methylation pattern in insulinomas.

14 his difference was present in all nine human insulinomas.

15 he understanding of the molecular biology of insulinomas.

16 est in ileal NETs and may also be helpful in insulinomas.

17 eatic beta-cell mass and detection of benign insulinomas.

18 n to be highly efficient in the detection of insulinomas.

19 s feasible and sensitive in detecting benign insulinomas.

20 ucagonlike peptide-1 receptor-overexpressing insulinomas.

21 toxic to cultured rat INS-1 (transformed rat insulinoma-1) beta-cells.

22 d 44 pancreatic primary tumors, including 12 insulinomas, 28 nonfunctioning endocrine tumors, and fou

23 Pdx1 expression was reduced in mouse insulinoma 6 (MIN6) cells by delivering small hairpin RN

24 We report that exposure of mouse insulinoma 6 cells to high concentrations of glucose res

25 a pancreatic beta-cell-like cell line (mouse insulinoma 6 clone K8).

26 cted pharmacological approaches in the mouse insulinoma-6 (Min6) cell line, we demonstrate that eleva

27 NMDAR-mediated signaling was observed in rat insulinoma 832/13 cells and in human beta-cells, indicat

28 that insulin 2 (Ins2) mRNA expression in rat insulinoma 832/13 cells is markedly increased by wild-ty

29 the RIP1-Tag2 model are well-differentiated insulinomas, a subset of tumors had lost multiple marker

30 Dosimetric estimations suggested that the insulinoma absorbed dose ranges from 30.3 to 127.8 Gy.

31 for dosimetry studies estimating the maximum insulinoma absorbed dose that could be achieved without

32 small microparticles, mainly EXO, from mouse insulinoma and examined their activities to stimulate th

33 correctly identified 48 of 49 patients with insulinoma and excluded the diagnosis in 64 of 65 contro

34 arlier, we had cloned IG20 cDNA from a human insulinoma and had shown that IG20/MADD can encode six d

35 oligomers but not monomers in pancreatic rat insulinoma and human islet cells.

36 The co-culturing of insulinoma and islet-derived endothelial cell (iEC) line

37 c mouse models of cancer (RIP1-Tag2 model of insulinoma and MMTV-PyMT model of breast cancer).

38 abeling in human IAPP transgenic mice, human insulinoma and pancreas from humans with and without T2D

39 lanoma, lung carcinoma and pancreatic B-cell insulinoma and provide evidence that loss of pericyte FA

40 differential expression of proteins between insulinoma and their paired tissues by proteomic analysi

41 rigenesis; miR-204 is primarily expressed in insulinomas and correlates with immunohistochemical expr

42 ations include preoperative visualization of insulinomas and discrimination between focal and diffuse

43 aroscopic surgical procedures for removal of insulinomas and focal lesions in CHI.

44 Surgical treatment of insulinomas and focal lesions in congenital hyperinsulin

45 The treatment of choice for insulinomas and focal lesions in congenital hyperinsulin

46 TPA-exendin-4 SPECT/CT correctly detected 19 insulinomas and four additional positive lesions (two is

47 Insulinomas and gastrinomas comprise the majority of fun

48 offer higher sensitivity in the detection of insulinomas and imaging of beta-cell mass in diabetic pa

49 fore seems to be a general characteristic of insulinomas and is estimated to contribute about 90% to

50 st cancers, colorectal cancer, melanoma, and insulinoma) and other diseases including vascular defect

51 ckdown, in MEN1-associated beta cell tumors (insulinomas), and also in human sporadic insulinomas.

52 re deep DNA methylome sequencing on 19 human insulinomas, and five sets of normal beta cells.

53 P-NETs, which include gastrinomas, insulinomas, and non-functioning tumours, occur in more

54 cid decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes.

55 Insulinomas are beta-cell tumors that cause hypoglycemia

56 Insulinomas are beta-cell tumours characterised by uncon

57 Small benign insulinomas are hard to localise, leading to difficultie

58 Insulinomas are pancreatic islet tumors that inappropria

59 Pancreatic insulinomas are rare neoplasms that are present in vario

60 Human insulinomas are rare, benign, slowly proliferating, insu

61 a subunits was detected in betaTC3 and NIT-1 insulinomas as well as in primary islets, with integrin

62 Insulinoma associated 1 (Insm1) plays an important role

63 These IPs are insulinoma-associated 1 (Insm1)(+)/BTG family member 2 (

64 The zinc-finger transcription factor insulinoma-associated 1 (Insm1, previously IA-1) is expr

65 d decarboxylase (65-kDa isoform; GAD65), and insulinoma-associated Ag-2 (IA-2), and peptides were elu

66 antibodies (IAA), GAD autoantibodies (GADA), insulinoma-associated antigen 2 autoantibodies (IA-2A),

67 antibodies to glutamic acid decarboxylase or insulinoma-associated antigen 2, or diabetes were observ

68 A novel cDNA, insulinoma-associated antigen-1 (IA-1), containing five

69 GAD autoantibodies (GADAs), insulinoma-associated antigen-2 antibodies (IA-2As), and

70 acid decarboxylase autoantibodies (GADA) and insulinoma-associated antigen-2 autoantibodies (IA-2A) w

71 for insulin, glutamic acid decarboxylase, or insulinoma-associated antigen-2 autoantibodies on 2 cons

72 Insulinoma-associated protein (IA)-2beta, also known as

73 form of glutamic acid decarboxylase (GAD65), insulinoma-associated protein 2 (IA-2), and zinc transpo

74 ecific for either known autoantigens (GAD65, insulinoma-associated protein 2 (IA2), IA2beta/phogrin,

75 antibodies to insulin (IAAs), GAD65 (GADAs), insulinoma-associated protein 2 (IA2As), and ZnT8 (ZnT8A

76 ere hypoglycemia nor positivity to GAD65 and insulinoma-associated protein 2 antibodies was associate

77 posttransplant autoantibodies (GAD antibody, insulinoma-associated protein 2 antigen, zinc transporte

78 IA-2 (insulinoma-associated protein 2), a major autoantigen in

79 oform of glutamic acid decarboxylase), IA-2 (insulinoma-associated protein IA-2) or insulin, alone or

80 onses to beta-cell autoantigens (proinsulin, insulinoma-associated protein, and GAD65 peptides) were

81 cell autoantibodies, insulin autoantibodies, insulinoma-associated protein-2 autoantibodies, and GAD

82 Insulinoma-associated-1 (INSM1) is a key protein functio

83 nsulin, glutamic acid decarboxylase, and the insulinoma-associated-2 (IA-2) molecule were analyzed us

84 Similarly, in insulinoma-bearing mice, the early postnatal development

85 in 1 and rat insulin 2 promoters in the MIN6 insulinoma beta cell line.

86 induced ER stress signaling assessed in MIN6 insulinoma beta cells.

87 n fatty acyl-carnitines promoted IS from rat insulinoma beta-cells (INS-1) as well as primary mouse i

88 up B, the presence of low-Km hexokinase-I in insulinoma beta-cells (not in adjacent islets) was revea

89 effect of carbidopa on (18)F-FDOPA uptake in insulinoma beta-cells and an insulinoma xenograft model

90 Allogeneic murine insulinoma beta-TC3 cells and primary islets from BALB/C

91 n1 knockout mice develop multiple pancreatic insulinomas, but this occurs many months after loss of b

92 of exendin-4 derivatives for the imaging of insulinomas by high-resolution PET at early or late time

93 ions for reducing beta-cell proliferation in insulinomas by inhibiting phospho-HLXB9 or its interacti

94 ent potential new tracers for the imaging of insulinomas by PET.

95 Pancreatic insulinomas can be readily localized preoperatively with

96 oning and expression of mSTRPC4 from a mouse insulinoma cDNA library.

97 3C6]glucose, was compared in four clonal rat insulinoma cell 1-derived cell lines with varying degree

98 -O-(thio)triphosphate binding and INS1 832-3 insulinoma cell cAMP assays, BETP enhanced GLP-1(9-36)-N

99 the production of free radicals, induces rat insulinoma cell death by activation of a non-selective c

100 a cell line (PANC-1) and the endocrine human insulinoma cell line (CM) were applied for in vitro (11)

101 hermore, addition of monomeric IAPP to a rat insulinoma cell line (INS-1) resulted in decreased cell

102 in the pancreatic beta-cell line MIN6 (mouse insulinoma cell line 6) and islets of Langerhans that ag

103 LAG fusion protein was expressed in an INS-1 insulinoma cell line and then adsorbed to an anti-FLAG m

104 kdown of PTPMT1 expression in the pancreatic insulinoma cell line INS-1 832/13 alters the mitochondri

105 red with islets of rats and mice and the rat insulinoma cell line INS-1 832/13.

106 of human islets, rat beta-cells, and the rat insulinoma cell line INS-1E were examined.

107 We employed the mouse insulinoma cell line MIN6 to perform in vitro characteri

108 cruited to the insulin promoter in the mouse insulinoma cell line MIN6 when cells are switched from h

109 ee genetically modified strains of the mouse insulinoma cell line MIN6, each of which expressed key i

110 lated by O-linked glycosylation in the mouse insulinoma cell line MIN6.

111 d insulin secretion in rodent islets and the insulinoma cell line MIN6.

112 B2 can be phosphorylated in Rin cells (a rat insulinoma cell line) and cultured chromaffin cells, but

113 Cells of the insulinoma cell line, betaTC3, were stably transfected w

114 In addition, incubation of an insulinoma cell line, betaTC3, with an anti-TLR4 antibod

115 Using the 832/13 rat insulinoma cell line, we demonstrate using RNA interfere

116 sing the highly glucose-sensitive 832/13 rat insulinoma cell line, we demonstrated that glucose regul

117 ith either of two shRNAs in the INS-1 832/13 insulinoma cell line.

118 ly reduced Pdx1 expression in the Min6 mouse insulinoma cell line.

119 its genomic targets in NIT-1 cells, a mouse insulinoma cell line.

120 s glucose-stimulated insulin secretion in an insulinoma cell line.

121 ion in human pancreatic islets and the INS-1 insulinoma cell line.

122 Stably transformed insulinoma cell lines (MIN6) were created with small int

123 lysis on the four most widely studied rodent insulinoma cell lines and defined their flow cytometric

124 ency of adenovirus-mediated gene transfer in insulinoma cell lines and rat islets and 2) the rapidity

125 the hazards of interpreting data from rodent insulinoma cell lines as modeling normal cell cycle prog

126 cell proliferation in three different rodent insulinoma cell lines by arresting the cells in G2/M pha

127 lthough many studies using rodent islets and insulinoma cell lines have been performed to determine t

128 Rodent insulinoma cell lines may serve as a model for designing

129 rough CL and FAS is not required for GSIS in insulinoma cell lines or rat islets.

130 t-negative interference of SEL1L function in insulinoma cell lines severely impairs, whereas overexpr

131 etion from pancreatic beta-cells and related insulinoma cell lines.

132 he cell cycle at the protein level in rodent insulinoma cell lines.

133 ient to reduce the proliferation of cultured insulinoma cell lines.

134 ic condition, obestatin augments GSIS in rat insulinoma cells (INS-1) and in pancreatic islets from g

135 al activity assays in mouse islets and mouse insulinoma cells (MIN6) under different stimuli.

136 (Prolastin, human) were observed when murine insulinoma cells (MIN6) were exposed to tumor necrosis f

137 he expression profiles of glucose-responsive insulinoma cells 45 min after the addition of glucose, K

138 Loss of SIRT4 in insulinoma cells activates GDH, thereby upregulating ami

139 , and overexpression of iPLA(2)beta in INS-1 insulinoma cells amplifies, glucose-stimulated insulin s

140 y that enables the study of granule aging in insulinoma cells and beta-cells of knock-in mice through

141 echanism, we overexpressed human IAPP in rat insulinoma cells and freshly isolated human islets.

142 um signaling and energy metabolism in INS-1E insulinoma cells and human islet beta cells.

143 in NAD(P)H autofluorescence in both betaTC3 insulinoma cells and islets in a manner consistent with

144 reased IRS-2 protein expression in INS-1/832 insulinoma cells and mouse islets, whereas IRS-2 mRNA le

145 ncrease the anti-apoptotic protein Bcl-XL in insulinoma cells and mouse islets.

146 APK is activated by phosphorylation in INS-1 insulinoma cells and mouse pancreatic islets, that this

147 mall interfering RNA specific for pdx-1 into insulinoma cells and pancreatic islets to diminish endog

148 To study Set7/9 function, we depleted insulinoma cells and primary mouse islets of Set7/9 prot

149 is transiently activated by nitric oxide in insulinoma cells and rat islets following IL-1 treatment

150 both in vitro and in vivo approaches (mouse insulinoma cells and SPL-deficient mice), that SPL is a

151 are remarkably similar to those observed for insulinoma cells and suggest that this family of non-sel

152 CAP proteins were present in the nucleus of insulinoma cells and that endogenous INSM1 protein was c

153 itor thapsigargin induces apoptosis in INS-1 insulinoma cells and that this is inhibited by a bromoen

154 MS4 and MS6) were examined using 832/13 rat insulinoma cells as well as rodent and human islets.

155 previously reported that apoptosis of INS-1 insulinoma cells due to thapsigargin-induced ER stress w

156 s issue, we initially demonstrated that MIN6 insulinoma cells express functional M3Rs and that RGS4 w

157 solated rat pancreatic islets, whereas INS-1 insulinoma cells expressed only EDG-1, -2, -3, and -5 mR

158 Finally, this compound protected NIT-1 insulinoma cells from interleukin-1beta and alloxan cyto

159 tion (gammaH2AX formation) in rat islets and insulinoma cells in a nitric oxide- and ATM-dependent ma

160 kine-resistant cell lines by growth of INS-1 insulinoma cells in iteratively increasing concentration

161 Recordings of Kv2.1 currents from INS-1 insulinoma cells incubated with AA (5 mum) and subjected

162 ckdown of Pdx1 gene expression in mouse MIN6 insulinoma cells induced apoptotic cell death with an in

163 Consistently, CDK4 knockdown in INS-1 insulinoma cells inhibited glucose-stimulated cell cycle

164 retrograde transport in isolated islets and insulinoma cells mimicked the phenotype of Asna1(beta-/-

165 ria from liver, pancreatic islets, and INS-1 insulinoma cells or adding glucose to intact INS-1 cells

166 ne expression was knocked down in mouse MIN6 insulinoma cells resulting in apoptotic cell death that

167 n, and short interfering RNA to PDX1 in Min6 insulinoma cells results in the induction of normally un

168 d with GG-labeled encapsulated mouse betaTC6 insulinoma cells returned to normal within 1 week after

169 LA(2)beta) activity in pancreatic islets and insulinoma cells suggest that iPLA(2)beta participates i

170 tion of iPLA(2)beta in pancreatic islets and insulinoma cells suppresses, and overexpression of iPLA(

171 Subjecting insulinoma cells to oxidative stress induces iPLA(2)beta

172 rin expression in human pancreas and in MIN6 insulinoma cells was studied by Western blot, PCR, confo

173 Such events in INS-1 insulinoma cells were found to include activation of cas

174 ulated in vitro by chronic culture of 832/13 insulinoma cells with high concentrations of free fatty

175 KN93 reduced arachidonate release from INS-1 insulinoma cells, and both inhibit insulin secretion.

176 aling significantly reduces proliferation of insulinoma cells, and expression of Hedgehog signaling t

177 glucose dependent insulin secretion in NIT-1 insulinoma cells, and high insulin expression in the pre

178 th rat and human pancreatic islets and INS-1 insulinoma cells, and its attachment to cellular protein

179 ed p125 tyrosine phosphorylation in beta-TC3 insulinoma cells, beta-HC9 cells, and in freshly isolate

180 e peroxynitrite generation by rat islets and insulinoma cells, either with or without phorbol 12-myri

181 most potent GHRH agonist MR403 was tested on insulinoma cells, isolated rat islets, and adrenal beta-

182 extrans to study insulin granule dynamics in insulinoma cells, normal mouse islets, and primary pancr

183 In betaTC3 insulinoma cells, PDE7A1 co-localizes with PKA II in the

184 Isl-1(L/L); Pdx1-CreER(Tm) mice and betaTC3 insulinoma cells, respectively.

185 ed in electrophysiological recordings of rat insulinoma cells, which are known to express K(V)2 chann

186 we determine the role of mammalian EIPR1 in insulinoma cells.

187 cked down Irs2 gene expression in mouse MIN6 insulinoma cells.

188 oxidation damage caused by palmitic acid in insulinoma cells.

189 tion and revealed an antiapoptotic effect on insulinoma cells.

190 ted for enhancer activity in 832/13 and MIN6 insulinoma cells.

191 Smad3 action in promoter-reporter assays in insulinoma cells.

192 XA2 protein but not RNA expression in INS-1E insulinoma cells.

193 cycling and/or cytosolic NADPH production in insulinoma cells.

194 le and by small interfering RNA silencing in insulinoma cells.

195 rates in primary rat beta-cells to those in insulinoma cells.

196 , and release of insulin from mouse beta-TC6 insulinoma cells.

197 n-activated protein kinase in pancreatic and insulinoma cells.

198 plifies insulin secretory responses in INS-1 insulinoma cells.

199 demonstrated by RT-PCR in rodent islets and insulinoma cells.

200 e obtained using primary rat islets or Min-6 insulinoma cells.

201 loid deposition, and cytotoxicity in RIN-m5F insulinoma cells.

202 s into the tricarboxylic acid (TCA) cycle in insulinoma cells.

203 ctively blocked GLT-induced apoptosis in rat insulinoma cells.

204 nd its target genes in pancreatic islets and insulinoma cells.

205 26RFa stimulates insulin production by MIN6 insulinoma cells.

206 Neuroendocrine pancreatic cancer (insulinoma) cells that do not produce insulin-like growt

207 ulin mRNA was increased more than 50-fold in insulinomas compared with normal islets, and this differ

208 We aimed to prospectively assess the insulinoma detection rate of single-photon emission CT i

209 ydroxy-l-phenylalanine ((18)F-FDOPA) PET for insulinoma diagnosis.

210 t the pathway level that the majority of the insulinomas display mutations, copy number variants and/

211 alculations to estimate the maximum absorbed insulinoma dose that could be achieved if exendin were t

212 c and inflammatory stresses applied to human insulinoma EndoC-betaH1 cells.

213 taneously with phosphatase-on-the-granule-of-insulinoma-enhanced green fluorescent protein.

214 on level of caspase 8 is markedly reduced in insulinomas from Men1(+/-) mice.

215 days after injection for the demarcation of insulinomas from the kidneys represent current limitatio

216 Recently, we identified Insulinoma-Glucagonoma clone 20 (IG20) that can render c

217 Patients with insulinoma had lower glucose levels and higher insulin a

218 d targeted sequencing revealed that 14 of 43 insulinomas harbored the identical somatic mutation in t

219 Proteomic study on insulinoma has been rarely reported.

220 Reasoning that insulinomas hold the "genomic recipe" for beta cell expa

221 using distinct clinical endocrine syndromes (insulinoma [hypoglycemia], gastrinoma [Zollinger-Ellison

222 eath, dedifferentiation, or the formation of insulinomas if cooverexpressed with Bcl-xL, an inhibitor

223 A accumulation in RIN-m5F cells but improved insulinoma imaging in vivo.

224 TA-exendin-4 PET/CT correctly identified the insulinoma in 4 of 4 patients, whereas (111)In-DOTA-exen

225 -exendin-4 SPECT/CT correctly identified the insulinoma in only 2 of 4 patients.

226 vity, pericytes on capillary-size vessels in insulinomas in RIP-Tag2 transgenic mice expressed both d

227 idney uptake, enabling a better detection of insulinomas in the tail and head of the pancreas.

228 tently, siRNA-mediated Shp2-knockdown in rat insulinoma INS-1 832/13 cells resulted in decreased insu

229 is expressed in human islets and pancreatic insulinoma INS-1 and MIN6 cells.

230 tion of RESP18HD upon exocytosis of SGs from insulinoma INS-1 cells is associated with cleavage of it

231 ntic vacuoles were also observed in cultured insulinoma INS-1 cells upon CRISPR/Cas9-mediated removal

232 We have previously described rat insulinoma INS-1-derived cell lines with robust or poor

233 binding to the extracellular surface of rat insulinoma INS-1E cells that stably expressed a tagged h

234 ZnT8A binding was detected on live rat insulinoma INS-1E cells, and the binding specificity was

235 on of the JNK pathway in human islets and in insulinoma (INS 832/13) cells.

236 tudy demonstrates that lactogens protect rat insulinoma (INS-1) cells and primary mouse beta cells ag

237 in both primary mouse beta-cells and in rat insulinoma (INS-1) cells, indicating a direct effect on

238 independent robustly glucose-responsive rat insulinoma (INS-1-derived) cell lines and in primary rat

239 Insulinomas (INS) are the most common human and canine f

240 Knockout (KO) of WFS1 in rat insulinoma (INS1) cells impaired calcium homeostasis and

241 Insulinoma is a medical case in which the person is reco

242 Ga-DOTA-exendin-4 PET/CT in detecting hidden insulinomas is feasible.

243 tion, operative management, and follow-up of insulinomas is undetermined.

244 Stimulation of the MIN6 insulinoma line and primary rat islets with CRF also act

245 Using the Ins-1 rat insulinoma line, we demonstrate that activated Rap1A, bu

246 viability and mitochondrial activity of rat insulinoma m5F (RINm5F) cells.

247 at understanding the molecular complexity of insulinoma may be a valuable approach to diabetes drug d

248 ant with increased translation efficiency in insulinomas might explain how these tumours maintain hig

249 suppression of Pdx1 increases death of mouse insulinoma MIN6 beta-cells associated with dissipation o

250 s and target genes of phospho-HLXB9 in mouse insulinoma MIN6 beta-cells.

251 Using the mouse insulinoma MIN6 cell line and pancreatic islets, we inve

252 this study, microarray analysis of the mouse insulinoma MIN6 cell line revealed that the transcriptio

253 -induced dynamic Zn(2+) secretion from mouse insulinoma MIN6 cells and primary mouse and human pancre

254 trated that down-regulation of Nck1 in mouse insulinoma MIN6 cells results in faster dephosphorylatio

255 his study, we introduced an shRNA into mouse insulinoma MIN6 cells to deplete Pdx1 and found that exp

256 Moreover, CNO treatment of mouse insulinoma (MIN6) cells expressing the Rq(R165L) constru

257 Mouse insulinoma (MIN6) cells were administered with fatty aci

258 nic kidney cell line 293T (HEK293T) or mouse insulinoma (MIN6) cells.

259 that decrease insulin secretion from murine insulinoma MIN6B1 cells in response to the GLP-1 analog

260 A mouse insulinoma model was created with NIT-1 cells.

261 D3 overexpression protected the NOD-derived insulinoma NIT-1 cell line from cytokine-induced apoptos

262 se 1/2 and nuclear factor-kappaB pathways in insulinoma NIT-1 cells, and inhibitors of either pathway

263 ded with reduced Cblb and increased c-Met in insulinomas of two mouse models of menin loss.

264 Finally, exposure of insulinomas or beta cells to glutamine induced Akt phosp

265 ed the weak transfer of ZnT8 reactivity from insulinomas or primary beta-cells to APC for presentatio

266 rom excessive beta-cell proliferation (e.g., insulinoma) or insufficient beta-cell mass (e.g., diabet

267 and can be due either to beta-cell tumours (insulinomas) or beta-cell hyperplasia.

268 Insulinomas (pancreatic islet beta cell tumors) are the

269 ms a therapeutically targetable mechanism of insulinoma pathogenesis.

270 ar scintigraphic (111)In-exendin images of 5 insulinoma patients were used for dosimetry studies esti

271 secretion by perifused fragments of 10 human insulinomas permitted their subdivision into three funct

272 erize the genomic and molecular landscape of insulinomas relative to normal beta cells.

273 We have recently demonstrated that insulinoma-released EXOs can stimulate the autoimmune re

274 Recent biochemical diagnostic guidelines for insulinomas require demonstration of hypoglycemia with i

275 Sixty-one patients with a diagnosis of insulinoma requiring surgery at a tertiary care center b

276 ificantly down-regulated and up-regulated in insulinomas, respectively.

277 perplasia) and one false negative (malignant insulinoma) result was identified in separate patients b

278 ionality would suppress proliferation of rat insulinoma (Rin) cells comparably to wild-type Cx37 (Cx3

279 tumor-associated Ag in spontaneously arising insulinomas (RIP-Tag2-HA mice), a high proportion of clo

280 racted RNA from nine laser-captured surgical insulinoma samples and from isolated islets of nine dono

281 Rat primary beta-cells and mouse insulinomas showed an adhesion remodeling during GSIS re

282 NA-binding motifs, was isolated from a human insulinoma subtraction library.

283 Being highly expressed in insulinomas, the glucagonlike peptide-1 receptor (GLP-1R

284 Human insulinomas thus show distinct, though not completely he

285 e genomic and epigenetic landscapes of human insulinomas to gain insight into possible pathways for t

286 or beta cell expansion, we surveyed 38 human insulinomas to obtain insights into therapeutic pathways

287 We used insulinomas transfected with the CIITA transactivator, w

288 ta and pHLXB9 can serve as novel targets for insulinoma treatment and have implications for understan

289 ransiently transfected islet-derived hamster insulinoma tumor and betaTC-3 cells revealed that the pr

290 Insulinoma was excluded in 65 patients; follow-up for a

291 ess T Ag from the RIP and develop pancreatic insulinomas, we demonstrate that epitope IV- but not epi

292 t is involved in insulin production by human insulinomas, we extracted RNA from nine laser-captured s

293 ed specimens from each patient, and multiple insulinomas were identified in one.

294 Multiple insulinomas were noted in 8% of cases and were more comm

295 ents histologic diagnosis confirmed a benign insulinoma, whereas one patient refused surgery despite

296 ndolent but ultimately malignant, except for insulinomas, which predominantly are benign.

297 preclinical research specifically focused on insulinomas, with potential translational implications.

298 FDOPA uptake in insulinoma beta-cells and an insulinoma xenograft model in mice.

299 Insulinoma xenografts in carbidopa-treated mice showed s

300 y7 and optoacoustically visualized beta-cell insulinoma xenografts in vivo for the first time.